CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that has become one of the most widely referenced peptides in preclinical growth hormone axis research. It exists in two distinct forms: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC, the latter also known as Modified GRF (1-29). Understanding the differences between these two variants is essential for researchers designing experiments involving GHRH analogs.
What Is CJC-1295?
CJC-1295 is based on the first 29 amino acids of human GHRH, with four amino acid substitutions at positions 2, 8, 15, and 27 that confer resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). These modifications dramatically extend the biological half-life compared to native GHRH(1-29), which is degraded within minutes in plasma. The base peptide without DAC, often called Modified GRF (1-29) or Mod GRF, retains these protective substitutions and has a half-life measured in approximately thirty minutes in preclinical models.
What Is DAC?
The Drug Affinity Complex is a chemical modification in which a reactive lysine residue on the peptide is conjugated to maleimidopropionic acid, which then binds covalently to serum albumin following injection. This albumin binding creates a large molecular complex that is protected from renal filtration and enzymatic degradation. The result is a dramatically extended half-life, reported in preclinical and early clinical pharmacokinetic studies to exceed six to eight days.
This conjugation technology was originally developed by ConjuChem Biotechnologies and represents a general strategy for extending the pharmacokinetic profile of peptide therapeutics. The DAC modification does not alter the receptor binding domain of the peptide, meaning that the albumin-bound complex retains its ability to bind and activate the GHRH receptor on pituitary somatotroph cells.
Pharmacokinetic Differences
The practical difference between the two variants comes down to duration of activity. Modified GRF (1-29) without DAC has a relatively short half-life and produces an acute, pulsatile increase in growth hormone levels when administered to research animals. This pulse-like profile more closely mimics the natural physiological pattern of growth hormone secretion, which occurs in discrete bursts rather than as a sustained elevation.
CJC-1295 with DAC, by contrast, produces a sustained elevation of growth hormone levels over an extended period. Preclinical data and early human pharmacokinetic studies demonstrated that a single administration could elevate mean growth hormone and IGF-1 levels for several days. This continuous elevation pattern differs fundamentally from natural physiology, which is characterized by pulsatile secretion with low trough levels between peaks.
Research Protocol Considerations
The choice between DAC and non-DAC variants depends on the specific research question. Investigators studying acute growth hormone pulse dynamics, receptor desensitization kinetics, or the effects of pulsatile versus sustained growth hormone exposure in animal models will generally prefer Modified GRF (1-29) without DAC. Its shorter duration allows for controlled dosing schedules that can replicate or modulate natural pulse patterns.
Researchers interested in studying the effects of sustained growth hormone axis activation, or those conducting longer-term animal studies where less frequent dosing is desirable for practical reasons, may select CJC-1295 with DAC. The extended half-life reduces the number of administrations required, which can be advantageous in chronic exposure study designs.
In many preclinical protocols, Modified GRF (1-29) is co-administered with a growth hormone secretagogue peptide such as Ipamorelin. The rationale is that GHRH analogs and GHSR-1a agonists act through complementary mechanisms on pituitary somatotrophs, and co-administration in animal models has been observed to produce synergistic growth hormone release.
Handling and Storage
Both variants are supplied as lyophilized powders and should be stored at negative twenty degrees Celsius. Reconstitution is typically performed with bacteriostatic water. After reconstitution, both should be stored at two to eight degrees Celsius and used within three to four weeks. Researchers should note that the DAC variant, due to its albumin-binding chemistry, requires careful handling to avoid premature conjugation with proteins in the reconstitution environment.
Research Use Disclaimer
Both CJC-1295 with DAC and Modified GRF (1-29) are sold exclusively for in-vitro and preclinical research applications. They are not intended for human use and have not been approved by any regulatory body for therapeutic purposes. Researchers should always verify product identity and purity via an independent Certificate of Analysis before incorporating these compounds into experimental protocols.